Nymox's statin drugs may reduce risk of developing Alzheimer's, article says

By Angela McDaniels

Seattle, Dec. 19 - Nymox Pharmaceutical Corp. said a recent article in the American Journal of Medicine suggests that statin drugs may reduce the risk of developing Alzheimer's disease.

Nymox holds global patent rights to statin drugs for the treatment of Alzheimer's disease.

In addition to lowering cholesterol levels, statins may also help suppress production of an amyloid protein believed to play a role in the Alzheimer's disease process, the company said. Statins also improve blood flow function and reduce inflammation, each of which may positively impact the risk of developing Alzheimer's disease.

The article was published in the December issue of The American Journal of Medicine and was authored by Steven DeKosky of the University of Pittsburgh Medical Center Health System.

Nymox is a biopharmaceutical company based in Hasbrouck Heights, N.J., that develops therapeutics and diagnostics for the aging population.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.